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Essentials
 Disorders of hemostasis can lead to delayed and defec-
tive wound healing.
 In hemophilia B (HB) mice, 7 days of Factor (F)IX or
VIIa are needed to normalize wound healing.
 One dose of a highly active FVIIa variant (DVQ)
restored normal wound closure time in HB mice.
 Coagulation factors with enhanced activity may acquire
biological effects not due to hemostasis.
Summary. Introduction: We have previously reported that
hemophilia B (HB) mice have delayed healing of cuta-
neous wounds and alterations in wound histology. Admin-
istration of a single dose of either factor IX or
recombinant activated FVII (rFVIIa) (NovoSeven) prior
to wounding did not improve wound closure time or his-
tology. The activated FVII analog DVQ (V158D, E296V
and M298Q mutations) was designed to have higher tissue
factor-independent activity than rVIIa. We hypothesized
that a single dose of DVQ would be more effective in
restoring wound healing in HB mice. Methods: Cutaneous
punch wounds were made on the backs of HB and wild-
type mice, and the time to wound closure was monitored.
HB mice were treated with a dose of rFVIIa (10 mg kg1)
or DVQ (1 mg kg1) that corrected the tail bleeding time.
Skin samples were taken at various time points after
wounding, fixed, and stained, and the histology was exam-
ined. Results: As previously reported, wound closure times
in HB mice given one dose of rFVIIa were not improved
over those in untreated HB mice. Surprisingly, healing
times in HB mice treated with an equally hemostatic dose
of DVQ were normalized to that in wild-type mice. How-
ever, DVQ did not correct all histologic abnormalities in
HB mice. Conclusions: As the doses of DVQ and rFVIIa
were chosen to support comparable levels of hemostasis,
our data suggest that the improved healing seen with DVQ
is not solely attributable to its hemostatic activity. It is
possible that the improved wound healing arises through
the effect of DVQ on cell signaling mechanisms.
Keywords: angiogenesis inhibitors; epithelium; hemophil-
ia; hemostasis; thrombin.
Introduction
We have previously found that healing of cutaneous
punch biopsy wounds is delayed in hemophilia B (HB)
mice [1]. In addition to the delay in healing, HB mice also
show histologic abnormalities of the wound site [1]. These
include a delay in the influx of macrophages, increased
numbers of angiogenic vessels, and increased iron deposi-
tion. In addition, HB mice suffer delayed bleeding, with
some hematomas forming even after the surface wound is
completely closed. The late hematomas occur in the tissue
plane just below the dermis, where blood vessels are
located that serve as the source of angiogenic sprouts.
A single dose of replacement (factor IX) therapy or a sin-
gle dose of recombinant activated FVII (rFVIIa) at the
time of biopsy wound placement does not normalize heal-
ing in HB mice, or prevent late hematoma formation [2].
Hemostatic treatment for at least 5 days is required to
normalize healing in this model [3].
DVQ (also called NN1731 and Vatreptacog alfa) is a
rationally designed analog of activated FVII (FVIIa) in
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which three amino acids are changed in the catalytic
domain (V158D/E296V/M298Q) [4]. It has increased
proteolytic activity as compared with FVIIa in the
absence of tissue factor (TF), but approximately the
same activity as FVIIa in the presence of TF [4]. DVQ
was developed as a potentially more effective ‘bypassing
agent’ for the management of bleeding in hemophilia
patients, based on the hypothesis that the hemostatic
effect of high-dose rFVIIa in this setting is primarily
attributable to its TF-independent activity on the surface
of activated platelets [5]. The DVQ variant was found to
have enhanced procoagulant and antifibrinolytic activi-
ties in an in vitro model of hemophilia relative to wild-
type (WT) FVIIa [6], and higher hemostatic efficacy in a
mouse hemophilia model [7]. In phase 1 to phase 3 clini-
cal trials, this analog was more potent than rFVIIa
[8,9]. However, clinical development was stopped when
some patients developed anti-drug antibodies [10]. We
hypothesized that DVQ might have a greater effect on
wound healing in our HB mouse model than rFVIIa,
because of its ability to support a higher level of throm-
bin generation.
Materials and methods
Animal model of wound healing
Adult WT mice (C57BL/6) and FIX-knockout (HB) mice
on a C57BL/6 background were used in these studies [11].
Wound healing studies were performed in accordance
with a protocol approved by the Institutional Animal
Care and Use Committee of the University of North Car-
olina at Chapel Hill. We used the cutaneous punch
biopsy wound model that we have previously reported
[1,2]. A three-millimeter biopsy punch wound was made
on the back of each WT and HB mouse. For HB mice
receiving factor therapy, a dose of either rFVIIa (Novo-
Seven; Novo Nordisk, Bagsvaerd, Denmark) or the DVQ
variant of FVIIa (a kind gift from E. Persson, Novo Nor-
disk) was administered by tail vein injection 30 min prior
to wounding. rFVIIa at 10 mg kg1 and DVQ at
1 mg kg1 were the doses required to prevent excess
bleeding in a tail clip model [7]. Some mice were also
dosed with 10 mg kg1 DVQ. The plasma half-life of
human rFVIIa is ~ 1 h in mice [7], whereas the plasma
half-life of DVQ is probably shorter, owing to its more
rapid inhibition by antithrombin [12]. In some experi-
ments, a solution of DVQ (10 lL of 1.8 mg mL1) was
applied topically to the wound site immediately after
punch biopsy placement.
Mice were given 480 mg of acetaminophen in 150 mL
of water for analgesia until day 4 after wounding. Wound
size was recorded daily, and the wound area was calcu-
lated. Mice were killed, and wounded skin was collected
at selected time points.
Microscopic evaluation of tissues
Collection of skin samples, handling, processing,
immunostaining and evaluation of tissue sections were
performed as previously described [1]. Briefly, skin from
the wound sites was pinned flat in 10% buffered formalin
for 12–24 h before being processed into paraffin. Speci-
mens were bisected and embedded with the wound center
up. Sections were stained with hematoxylin and eosin or
immunostained for vessel counts (anti-CD34; Serotec,
Raleigh, NC, USA). Antigen retrieval was performed
with DakoCytomation Target Retrieval Solution (Dako,
Carpinteria, CA, USA) before immunostaining. Angio-
genic vessels were counted as previously described [1].
Measurement of affinity of human FVIIa and DVQ for
mouse TF
The cDNA encoding the extracellular domain of mouse
TF was amplified from a mouse lung cDNA library
(which was purchased ~ 20 years ago from Stratagene;
the product has since been discontinued) with two pri-
mers: tataccatggcaggcattccagagaaag and ctaaatggatcct-
cattctcccaggaaactcttccattg. The amplified cDNA was
cloned into pET28a (Novagen, now EMD Millipore 4)
through NcoI and BamHI sites. The cloned sequence was
confirmed by the UNC-CH genome analysis facility.
Expression and purification of recombinant soluble mouse
TF protein were performed as previously described [13].
FVIIa binding and DVQ binding were assayed as the
increase in FX activation when they were bound to TF.
Although DVQ has higher activity than FVIIa in the
absence of TF, its activity is still increased by binding to
TF. Phosphatidylserine (PS), phosphatidylcholine (PC)
and phosphatidylethanolamine (PE) were from Avanti
Polar Lipids (Birmingham, AL, USA). Large unilamellar
vesicles (LUVs) with the composition 15% PS/41% PC/
44% PE were prepared as previously described [14]. The
assay was performed at room temperature in: 20 mM
HEPES (pH 7.5), 150 mM NaCl, 3 mM CaCl2, and
1 mg mL1 ovalbumin. The final concentrations of com-
ponents were: 0.1 nM soluble mouse TF, 60 lM LUVs,
150 nM FX (Enzyme Research Laboratories, South Bend,
IN, USA; repurified as in [15]), and 250 lM Pefachrome
activated FX (FXa) (Pentapharm, Basel, Switzerland),
with varied amounts of FVIIa or DVQ. FVIIa and DVQ
were mixed with soluble TF and LUVs for 5 min to allow
binding. FX and Pefachrome FXa were added, and FXa
cleavage of substrate was monitored.
Statistical evaluation
Wound sizes were compared by the use of Student’s
t-test, with Tukey’s correction for multiple comparisons.
The percentages of wounds closed at a given time point
© 2016 International Society on Thrombosis and Haemostasis
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were compared by the use of Fisher’s exact test [16]. Sta-
tistical analysis was performed with GRAPHPAD PRISM 65 .
Results and discussion
A single injection of DVQ normalizes wound closure in HB
mice
As shown in Fig. 1, a single injection of DVQ at the time
of punch biopsy placement normalized wound size (upper
left) and time to healing (lower left) in HB mice. HB mice
in our previous study were treated with 10 mg kg1
rFVIIa [2]. We treated HB mice with the same dose of
DVQ, and observed that the wound sizes were smaller
than those in untreated HB mice, and, surprisingly, that
the time to wound closure was normalized. DVQ is signif-
icantly more potent than rFVIIa in a tail clip bleeding
model in mice, with 1 mg kg1 having equivalent hemo-
static effectiveness as 10 mg kg1 rFVIIa [7], so we also
tested the lower dose. Wound sizes in the mice given a
single injection of either 1 mg kg1 or 10 mg kg1 DVQ
at the time of wounding were significantly smaller than
those in untreated HB mice (P < 0.05; Student’s t-test
with Tukey’s correction for multiple comparisons) at mul-
tiple time points, and were not significantly different from
those in WT mice. In addition, the time to complete clo-
sure of the skin defect in DVQ-treated mice was signifi-
cantly improved as compared with untreated mice (by
Fisher’s exact test [16]), and not different from that in
WT mice. A single injection of rFVIIa, as we have previ-
ously reported [2], did not significantly improve wound
size or time to healing in these experiments (Fig. 1). Thus,
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Fig. 1. Cutaneous wound healing in hemophilia B (HB) mice is normalized by one dose of DVQ. A punch biopsy wound was made on each
mouse. Some HB mice received an intravenous injection of DVQ (1 mg kg1 or 10 mg kg1) or activated factor VII (FVIIa) (10 mg kg1) at
the time of wounding. Each point is the mean of measurements from 17–20 HB mice and 11 wild-type mice. For HB mice treated with
10 mg kg1 DVQ, the numbers of mice were 25 (days 1–4), 23 (days 5–6), 13 (days 7–8), or seven (days 9–12). For 1 mg kg1 DVQ, the num-
bers of mice were 15 (days 1–6), 12 (days 7–8), or 10 (days 9–12). For FVIIa, the numbers of mice were 25 (days 1–2), 22 (days 3–4), 19
(days 5–6), 17 (days 7–8), 12 (days 9–10), and seven (days 11–12). The wound areas are plotted as a function of days after wounding in the
upper left panel. The bars represent the standard error of the mean. Wound sizes for days 4, 5 and 8 are shown in the upper right panel
(*P < 0.05 as compared with untreated HB mice; Student’s t-test). In this panel, the bars represent the standard deviation. The percentages of
wounds healed at each day after wounding are plotted in the lower left panel, and the percentages of wounds healed at day 9 are shown in a
bar graph in the lower right panel. A significantly greater proportion of wounds were healed in HB mice treated with 1 mg kg1 or 10 mg kg1
DVQ at days 9 and 10 than in other HB mice (*P < 0.05; Fisher’s exact test) 6; 10.
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a single dose of DVQ, unlike FIX and rFVIIa, could nor-
malize the time course of cutaneous healing in HB mice.
A single injection of DVQ does not normalize wound
histology in HB mice
One of the histologic abnormalities present in HB mice
following wounding is the presence of an excess of angio-
genic vessels around the wound bed. These vessels predis-
pose the HB mice to episodes of bleeding and hematoma
formation for an extended period of time following
wounding [17]. Therefore, we tested the hypothesis that a
dose of DVQ would also normalize angiogenesis follow-
ing wounding. However, as shown in Fig. 2, angiogenesis
in the wound bed was not normalized by a single injec-
tion of DVQ at the time of punch biopsy placement. The
vessel counts in HB mice treated with 10 mg kg1 DVQ
were not significantly different from those in untreated
HB mice at any time point, although both were signifi-
cantly greater than those in WT mice at 8 days after
wounding.
Topical application of DVQ improves wound healing in HB
mice
Intravenous infusion of equally hemostatic doses of DVQ
(1 mg kg1) and rFVIIa (10 mg kg1) had different
effects on wound closure; one dose of DVQ normalized
wound closure, whereas rFVIIa did not. This could be
the result of DVQ producing a more rapid burst of
thrombin generation than rFVIIa, leading to more rapid
hemostasis [18] and possibly a more favorable fibrin clot
structure to support healing. In fact, DVQ was found to
produce more rapid hemostasis in a randomized clinical
trial [10]. However, an alternative hypothesis is that DVQ
does not enhance epithelial wound closure solely because
of its hemostatic effect. Even though treatment with
DVQ normalized closure of the epithelial defect, it did
not normalize the underlying tissue histology – even at a
10-fold higher dose than required to restore surface clo-
sure. This suggests that DVQ might have a specific effect
on the squamous epithelium.
To begin testing this hypothesis, we examined the effect
of the topical application of DVQ to the wound surface.
As shown in Fig. 3, topical application of DVQ immedi-
ately after wounding of HB mice reduced wound sizes to
the point that they were not significantly different from
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Fig. 2. Angiogenesis in skin wounds is not normalized by one dose
of DVQ in hemophilia B (HB) mice. Angiogenesis was assessed by
counting vessel profiles in the wound area. Counts are expressed per
high-power field (HPF) (9 40). The scores were averaged for two
sections of three to seven wounds per time point. Angiogenesis at
day 8 was significantly greater in DVQ-treated or untreated HB mice
than in wild-type mice (*P < 0.05 as compared with wild-type mice;
Student’s t-test). Angiogenesis in DVQ-treated HB mice was not sig-
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those in WT controls. In addition, all wounds in DVQ-
treated HB mice were closed by day 10, which is the same
as what was seen in WT mice. Thus, topical DVQ nor-
malized wound size and the time to complete wound clo-
sure in HB mice.
The efficacy of topical DVQ suggests that it might be
acting through a receptor-mediated mechanism to
enhance squamous epithelial proliferation and/or migra-
tion. There are clear precedents for stimulation of cuta-
neous healing by components of the coagulation system.
Topical thrombin has been reported to enhance wound
healing via protease-activated receptor (PAR)-1 [19]. Both
activated protein C [20] and FXa [21] have been reported
to enhance wound healing via PAR-2. FVIIa in complex
with TF can activate PAR-2 [22]. FVIIa in complex with
the endothelial protein C receptor can activate PAR-1
[23]. Therefore, we hypothesize that the enhanced prote-
olytic activity of the DVQ variant may enable it to
directly cleave one or more PAR in the absence of a
cofactor, and thereby enhance epithelial healing.
Different effects of FVIIa and DVQ are not attributable to
differences in TF binding
It has previously been shown that human rFVIIa binds
extremely poorly to mouse TF [13]. It is possible that (hu-
man) DVQ has greater affinity for mouse TF than does
the wild type. However, as shown in Fig. 4, we found
that this was not the case. FVIIa and DVQ had similarly
poor affinity for the recombinant extracellular domain of
mouse TF (soluble TF). In contrast, mouse FVIIa bound
tightly to soluble TF. Thus, the beneficial effects of DVQ
on cutaneous wound healing are not mediated by binding
to TF.
Conclusions
We found that a single injection or topical application of
DVQ was able to normalize closure of a cutaneous punch
biopsy wound in HB mice. Neither a single dose of WT
rFVIIa nor a single dose of FIX could similarly normal-
ize the time to cutaneous wound closure. Even though
surface closure was enhanced by DVQ, the histology of
the underlying tissues was not normalized. Because DVQ
was more effective in normalizing cutaneous healing than
an equally hemostatic dose of FVIIa, we conclude that
the ability of DVQ to enhance would healing may not be
mediated solely by its hemostatic properties. A number of
coagulation proteins modulate other aspects of host
defense, such as inflammation, immune responses, and tis-
sue repair. This suggests that novel variants of coagula-
tion proteins can be designed not only to be more
effective hemostatic agents, but also to have additional
beneficial effects as biological modulators.
Addendum
M. Hoffman and D. M. Monroe: designed the study, col-
lected and analyzed the mouse data, and wrote the manu-
script. J.-Y. Chang: cloned and expressed mouse TF, and
conducted TF-binding studies. M. Ezban: provided a crit-
ical review of the study design, and edited the final manu-
script.
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